Table 1

 Selected laboratory and diagnostic findings and their change over time during treatment with basiliximab

February (before treatment)May (month 3)August (month 6)Reference
CK-MB, creatine kinase-myoglobin; CRP, C reactive protein; DLCOc SB, corrected carbon monoxide diffusion capacity using the single breath method; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; ; TLC, total lung capacity.
sIL2-R (Immulite assay in IU/ml)926.0556.0659.0<1000
Leucocytes (/nl)14.0211.528.634.5–11.0
CRP (mg/dl)<0.5
Creatine kinase (U/ml)2063940<145
CK-MB (U/ml)33n.d.n.d.<24
Myoglobin (µg/l)112n.d.n.d.<70
Creatinine (mg/dl)1.360.850.70<1.0
Proteinuria (mg/d)306NegativeNegative⩽150
Creatinine clearance (ml/min)58n.d.10690–130
Pericardial effusion (echocardiography in mm)15–30n.d.5–11
PAP (systole/diastole//mean in mm Hg)26/17//18n.d.26–30 (calculated)6–30/4–13//9–18
PCWP (systole/diastole//mean in mm Hg)6/5//4n.d.n.d.4–12
Cardiac index (l/min/m2)1.6n.d.n.d.2.5–4.0
FVC (l)1.79 (53.7)1.73 (52.1)1.43 (43.3)% of predicted given in ( )
FEV1(l)1.52 (52.9)1.46 (51.1)1.18 (41.3)% of predicted given in ( )
TLC (l)3.64 (69.6)3.57 (68.2)2.87 (54.9)% of predicted given in ( )
DLCOc SB (mmol/min/kPa)3.47 (39.8)n.d.2.91 (47.5)% of predicted given in ( )